HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. The call underscores the company's momentum following FDA clearances for its 3D ECG technology.
The company's platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. These clearances position HeartBeam to address critical gaps in cardiac monitoring, particularly for patients who require continuous assessment outside traditional clinical settings.
The limited commercial launch for arrhythmia assessment represents a key milestone, allowing the company to gather real-world data and refine its go-to-market strategy. Concurrently, the development of an extended-wear patch aims to provide longer monitoring periods, which could improve detection of intermittent arrhythmias. HeartBeam is also advancing heart attack detection capabilities and artificial intelligence programs to enhance diagnostic accuracy and clinical decision-making. These initiatives collectively aim to reduce the burden on healthcare systems by enabling earlier intervention and reducing unnecessary hospital visits.
The earnings call will be accessible via a live webcast on the company's investor relations page. A replay will be available shortly after the call. For more details, the full press release is available at https://ibn.fm/yN939. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
As with any forward-looking statements, HeartBeam cautions that actual results may differ materially due to risks and uncertainties. These include factors beyond management's control, as detailed in the company's filings with the SEC. Investors are encouraged to review the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
